Effectiveness of traditional Chinese medicine Jinlida granules as an add-on therapy for type 2 diabetes: A system review and meta-analysis of randomized controlled trials
中药津力达颗粒作为叠加疗法干预2型糖尿病的效果:随机对照试验的系统评价及meta分析
Abstract
enBackground
Jinlida granules are a commonly prescribed oral medication in China used in combination with antidiabetic drugs to lower blood glucose. The aim of this study was to systematically identify and pool the findings of randomized controlled trials evaluating the effectiveness and safety of Jinlida granules as add-on therapy for glycemic control in type 2 diabetes (T2D).
Methods
The China National Knowledge Infrastructure (CNKI), Wang Fang, PubMed, China biology medicine (CBM), and VIP Database for Chinese Technical Periodicals (VIP) databases were searched for papers regarding the effects of Jinlida granules in T2D published before 1 July 2018. A pooled analysis of extracted data was performed using random-effects models.
Results
In all, data were retrieved for 15 studies including 1810 individuals. Decreases in HbA1c were greater in groups receiving Jinlida granules as add-on therapy compared with control groups (n = 1820; mean difference − 0.66; 95% confidence interval − 0.72, −0.60; P < 0.00001; I2 = 38%). In addition, Jinlida granules reduced body mass index and had beneficial effects on homeostatic model assessment of β-cell function and homeostasis model assessment of insulin resistance. No obvious adverse events were reported.
Conclusions
Findings from this meta-analysis demonstrate additional benefits of Jinlida granules as an add-on therapy for T2D and that Jinlida granules are generally safe. Treatment with Jinlida granules provided clinically and statistically significant reductions in fasting plasma glucose, 2-hour post-load glucose, and HbA1c levels in patients with T2D. However, the findings should be interpreted with caution due to the small sample size and study limitations.
摘要
zh背景
津力达颗粒是我国常用的口服中成药，常与降糖药联合应用以降低血糖。本研究旨在系统评价津力达颗粒作为叠加疗法联合降糖药物治疗2型糖尿病的有效性和安全性。
方法
检索2018年7月1日前发表的关于津力达颗粒干预2型糖尿病随机对照试验的论文，使用CNKI、 Wangfang、PubMed、CBM、VIP数据库。使用随机效应模型对提取的数据进行meta分析。
结果
检索得到15项研究数据，包括1810名受试者。加用津力达颗粒的治疗组糖化血红蛋白下降明显高于对照组(n=1820；平均差= -0.66；95%置信区间(-0.72，-0.60)；P < 0.00001；I2 = 38%)。此外，津力达颗粒可降低体重指数，改善β细胞功能和胰岛素抵抗。服药期间无明显不良事件发生。
结论
meta分析结果显示，接受津力达颗粒作为叠加疗法干预2型糖尿病具有额外的受益且安全性高。口服津达颗粒治疗2型糖尿病的患者空腹血糖、餐后2小时血糖和糖化血红蛋白水平均有显著降低。然而，由于样本量小和研究的局限性，研究结果应谨慎解释。
